With the recent launches of Novo Nordisk’s Wegovy pill and Eli Lilly’s Foundayo, the obesity market has started to shift toward oral GLP-1 drugs. While Novo leverages its first-mover advantage with ...

The trend cycle moves at a breakneck clip, and keeping up can be a royal headache. Which is why, at the start of every new season, we like to wipe the slate clean and start fresh, setting last year’s ...